Stabilis

Lidocaine hydrochloride



Nombre comercial

Lidocard	Alemania, Finlandia
Lidocorit	Austria
Lidosen	Italia
Linisol	Bélgica
Pisacaina	Colombia, Ecuador, México, Venezuela
Plidocain	Polonia
Rapidocain	Suiza
Xilina	Rumania
Xylestesin	Austria, Brasil
Xylocain	Austria, Canadá, Dinamarca, Finlandia, Noruega, Polonia, Suecia, Suiza
Xylocaina	Brasil, Colombia, Ecuador, Italia, México, Portugal
Xylocaine	Arabia Saudita, Austria, Bélgica, Canadá, Egipto, Emiratos Árabes Unidos, Eslovenia, Estados Unidos de América, Francia, Gran Bretaña, Grecia, Irlanda, Japón, Luxemburgo, Malasia, Marruecos, Nueva Zelanda, Países Bajos, Polonia, Túnez
Xylocard	Arabia Saudita, Austria, Bélgica, Canadá, Francia, India, Islandia, Luxemburgo, Países Bajos, Suecia
Xylocitin	Alemania
Xyloneural	Alemania, Austria, Suiza

Estabilidad en solucion

		0.45 mg/ml	22°C	?	21			1126
		0.45 mg/ml	4°C		21			1126
		2 mg/ml	25°C		14			619
		0.45 mg/ml	22°C	?	21			1126
		0.45 mg/ml	4°C		21			1126
		2 mg/ml	25°C		14			619

	RL	2 mg/ml	25°C		14			619
PVC		0.45 mg/ml	22°C	?	21			1126
PVC		0.45 mg/ml	4°C		21			1126
PVC		2 mg/ml	25°C		14			619
PVC		0.45 mg/ml	22°C	?	21			1126
PVC		0.45 mg/ml	4°C		21			1126
PVC		2 mg/ml	25°C		14			619
PVC		4 mg/ml	30°C	?	120			1202
PVC		4 mg/ml	4°C		120			1202
PVC	RL	2 mg/ml	25°C		14			619
PP	∅	20 mg/ml	25°C		90			1715
PP	∅	20 mg/ml	25°C		90			1715
PP	∅	20 mg/ml	4°C		90			1715

Estabilidad en mezcla

	1 mg/ml	25°C		Bretylium tosilate : 10 mg/ml	48		705
	1 mg/ml	40°C		Bretylium tosilate : 10 mg/ml	48		705
	1 mg/ml	4°C		Bretylium tosilate : 10 mg/ml	7		705
	3,26 mg/ml	23°C-25°C		Dopamine hydrochloride : 0,8 mg/ml	24		738
	5,3 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4		2279
	1 mg/ml	25°C		Bretylium tosilate : 10 mg/ml	48		705
	1 mg/ml	40°C		Bretylium tosilate : 10 mg/ml	48		705
	1 mg/ml	4°C		Bretylium tosilate : 10 mg/ml	7		705
	9,1 mg/ml	23°C		Sodium bicarbonate : 7,6 mg/ml	91		3263
	9,1 mg/ml	5°C		Sodium bicarbonate : 7,6 mg/ml	91		3263
PVC	0.5 & 10 mg/ml	25°C		Tirofiban : 25 µg/ml	4		1420
PVC	1 mg/ml	25°C		Bretylium tosilate : 10 mg/ml	48		705
PVC	1 mg/ml	40°C		Bretylium tosilate : 10 mg/ml	48		705
PVC	1 mg/ml	4°C		Bretylium tosilate : 10 mg/ml	7		705
PVC	1 & 8 mg/ml	?	?	Ranitidine hydrochloride : 0,05 & 2 mg/ml	48		210
PVC	4 mg/ml	23°C		Flumazenil : 0,02 mg/ml	24		187

PVC		0.5 & 10 mg/ml	25°C		Tirofiban : 25 µg/ml	4	1420
PVC		1 mg/ml	25°C		Bretylium tosilate : 10 mg/ml	48	705
PVC		1 mg/ml	40°C		Bretylium tosilate : 10 mg/ml	48	705
PVC		1 mg/ml	4°C		Bretylium tosilate : 10 mg/ml	7	705
PVC		1 & 8 mg/ml	?	?	Ranitidine hydrochloride : 0,05 & 2 mg/ml	48	210
PP		10 mg/ml	-15°C		Ceftriaxone disodium : 450 mg/ml	56	279
PP		10 mg/ml	20°C		Ceftriaxone disodium : 450 mg/ml	24	279
PP		10 mg/ml	4°C		Ceftriaxone disodium : 450 mg/ml	10	279
PP		3,5 mg/ml	22°C	?	Epinephrine hydrochloride : 3,5 µg/ml Bleomycin sulfate : 0,75 mg/ml	1	3420
PP		3,5 mg/ml	4°C	?	Epinephrine hydrochloride : 3,5 µg/ml Bleomycin sulfate : 0,75 mg/ml	3	3420
PP	∅	9 mg/ml	4-7°C		Sodium bicarbonate : 7,8 mg/ml Epinephrine hydrochloride : 9 µg/ml	7	2878
PP	∅	18 mg/ml	4-7°C		Sodium bicarbonate : 7,8 mg/ml Epinephrine hydrochloride : 9 µg/ml	7	2878
PP	∅	9 mg/ml	4-7°C		Sodium bicarbonate : 7,8 mg/ml	28	2878
PP	∅	18 mg/ml	4-7°C		Sodium bicarbonate : 7,8 mg/ml	28	2878
PP		20 mg/ml	28°C		Ketamine hydrochloride : 2,5 mg/ml	48	4350
PP	∅	455 mg/ml	25°C		Magnesium sulfate : 2 mg/ml	168	4457
PP	∅	455 mg/ml	40°C		Magnesium sulfate : 2 mg/ml	168	4457
?		3,3 mg/ml	22°C-28°C	?	Daptomycin : 16,7 mg/ml	2	1937
?		20 mg/ml	25°C	?	Phenylephrine hydrochloride : 2,5 mg/ml	66	1331

Compatibilidades

		Lidocaine hydrochloride : 8 mg/ml Alteplase : 1 mg/ml		92
		Lidocaine hydrochloride : 4 mg/ml Alteplase : 0.5 mg/ml		240
		Lidocaine hydrochloride : 2 mg/ml Aminophylline : 1 mg/ml		619
		Lidocaine hydrochloride : 2 mg/ml Aminophylline : 1 mg/ml	RL	619
		Lidocaine hydrochloride : 2 mg/ml Aminophylline : 1 mg/ml		619
		Lidocaine hydrochloride : 8 mg/ml Amiodarone hydrochloride : 4 mg/ml		1036
		Lidocaine hydrochloride : 4 mg/ml Amiodarone hydrochloride : 1.8 mg/ml		242

	✓	Lidocaine hydrochloride : 4 mg/ml Amiodarone hydrochloride : 1.8 mg/ml	◆	242
	✓	Lidocaine hydrochloride : 8 mg/ml Amiodarone hydrochloride : 4 mg/ml	◆	1036
	✓	Lidocaine hydrochloride : 1 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
?	✗	Lidocaine hydrochloride Amphotericin B		5060
	✗	Lidocaine hydrochloride : 10 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	◆	921
	✓	Lidocaine hydrochloride : 8 mg/ml Argatroban : 1 mg/ml	◆	1963
	✓	Lidocaine hydrochloride : 10 mg/ml Bivalirudin : 5 mg/ml	◆	1713
	✓	Lidocaine hydrochloride : 1 mg/ml Bretylium tosilate : 10 mg/ml	▲	705
	✓	Lidocaine hydrochloride : 2 mg/ml Bretylium tosilate : 1 mg/ml	▲	619
	✓	Lidocaine hydrochloride : 2 mg/ml Bretylium tosilate : 1 mg/ml	◆	619
	✓	Lidocaine hydrochloride : 2 mg/ml Bretylium tosilate : 1 mg/ml	▲	1193
	✓	Lidocaine hydrochloride : 1 mg/ml Bretylium tosilate : 10 mg/ml	◆	705
	✓	Lidocaine hydrochloride	◆	619
	✓	Lidocaine hydrochloride	◆	1202
	✓	Lidocaine hydrochloride : 2 mg/ml Bretylium tosilate : 1 mg/ml	RL	619
	✓	Lidocaine hydrochloride : 2 mg/ml Bretylium tosilate : 1 mg/ml	◆	1193
	✓	Lidocaine hydrochloride : 10 mg/ml Caffeine : 10 mg/ml	∅	3964
	✓	Lidocaine hydrochloride : 2 mg/ml Calcium gluconate : 2 mg/ml	RL	619
	✓	Lidocaine hydrochloride : 2 mg/ml Calcium gluconate : 2 mg/ml	▲	619
	✓	Lidocaine hydrochloride : 5 >> 20 mg/ml Cefamandole nafate : 285 mg/ml	◆	612
?	✗	Lidocaine hydrochloride Cefamandole nafate		3546
2	✗	Lidocaine hydrochloride Cefazolin sodium		499
	✓	Lidocaine hydrochloride : 8 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	▲	4528
	✓	Lidocaine hydrochloride : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml	◆	3249
	✗	Lidocaine hydrochloride : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	◆	2269
?	✗	Lidocaine hydrochloride Ceftobiprole medocaril sodium		4650
	✓	Lidocaine hydrochloride : 8 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml	▲	3828

	✓	Lidocaine hydrochloride : 10 mg/ml Cefuroxime sodium		3687
	✓	Lidocaine hydrochloride : 1.25 mg/ml Cimetidine hydrochloride : 3 mg/ml	◆	1201
	✓	Lidocaine hydrochloride : 20 mg/ml Ciprofloxacin lactate : 2 mg/ml	◆	288
	✓	Lidocaine hydrochloride : 40 mg/ml Ciprofloxacin lactate : 2 mg/ml	◆	288
	✓	Lidocaine hydrochloride : 8 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml	◆	299
	✓	Lidocaine hydrochloride Daptomycin		2271
	✓	Lidocaine hydrochloride : 2 mg/ml Digoxin : 1 µg/ml	▲	619
	✓	Lidocaine hydrochloride : 8 mg/ml Diltiazem hydrochloride : 1 mg/ml	◆	524
	✓	Lidocaine hydrochloride : 4 mg/ml Dobutamine hydrochloride : 1 mg/ml	▲	1058
	✓	Lidocaine hydrochloride : 8 mg/ml Dobutamine hydrochloride : 2 mg/ml	◆	1041
	✓	Lidocaine hydrochloride : 4 mg/ml Dopamine hydrochloride : 0.8 mg/ml	◆	738
	✓	Lidocaine hydrochloride : 2 mg/ml Dopamine hydrochloride : 0.8 mg/ml	▲	619
	✓	Lidocaine hydrochloride : 9 & 18 mg/ml Epinephrine hydrochloride : 9 µg/ml	NaH CO3	2878
	✓	Lidocaine hydrochloride Eptifibatide		3934
	✓	Lidocaine hydrochloride : 20 mg/ml Etomidate : 2 mg/ml	∅	319
	✓	Lidocaine hydrochloride : 1 mg/ml Famotidine	◆	397
	✓	Lidocaine hydrochloride : 4 mg/ml Flumazenil : 0,02 mg/ml	◆	187
	✓	Lidocaine hydrochloride : 8 mg/ml Fosfomycin : 30 mg/ml	▲	4055
	✓	Lidocaine hydrochloride : 4 mg/ml Heparin sodium : 50 UI/ml	∅	317
	✓	Lidocaine hydrochloride : 0.13 mg/ml	▩	1338
	✓	Lidocaine hydrochloride	RL	619
	✓	Lidocaine hydrochloride Cefepime dihydrochloride		3548
	✓	Lidocaine hydrochloride : 8 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	◆	4528
	✓	Lidocaine hydrochloride : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
↓	✗	Lidocaine hydrochloride : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	✓	Lidocaine hydrochloride : 1 mg/ml Cloxacillin sodium : 100 mg/ml	●	3012
	✓	Lidocaine hydrochloride : 3,3 mg/ml Daptomycin : 16,7 mg/ml	▲	1937

		Lidocaine hydrochloride : 10 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Lidocaine hydrochloride : 2 mg/ml Digoxin : 1 µg/ml	RL	619
		Lidocaine hydrochloride Diltiazem hydrochloride		5090
		Lidocaine hydrochloride : 4 & 8 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Lidocaine hydrochloride : 10 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Lidocaine hydrochloride : 2 mg/ml Dopamine hydrochloride : 0.8 mg/ml	RL	619
		Lidocaine hydrochloride : 10 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Lidocaine hydrochloride : 2 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Lidocaine hydrochloride : 2 mg/ml Furosemide : 1 mg/ml		1232
		Lidocaine hydrochloride : 10 mg/ml	RL	4603
		Lidocaine hydrochloride : 2 mg/ml Calcium gluconate : 2 mg/ml		619
		Lidocaine hydrochloride : 5 >> 20 mg/ml Cefamandole nafate : 285 mg/ml		612
		Lidocaine hydrochloride : 5 mg/ml Cefazolin sodium		4966
		Lidocaine hydrochloride : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Lidocaine hydrochloride : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Lidocaine hydrochloride : 8 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Lidocaine hydrochloride : 20 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Lidocaine hydrochloride Cloxacillin sodium		4974
		Lidocaine hydrochloride Dexketoprofen		4981
		Lidocaine hydrochloride : 2 mg/ml Digoxin : 1 µg/ml		619
		Lidocaine hydrochloride : 4 mg/ml Dobutamine hydrochloride : 1 mg/ml		1058
		Lidocaine hydrochloride : 2 mg/ml Dopamine hydrochloride : 0.8 mg/ml		619
		Lidocaine hydrochloride : 4 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Lidocaine hydrochloride : 4 mg/ml Famotidine : 0.2 mg/ml		398
		Lidocaine hydrochloride : 8 mg/ml Fosfomycin : 30 mg/ml		4055
		Lidocaine hydrochloride : 4 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		403

		Lidocaine hydrochloride : 8 mg/ml Hetastarch : 60 mg/ml		1721
		Lidocaine hydrochloride Hyaluronidase		3184
		Lidocaine hydrochloride Hydroxocobalamin		3932
		Lidocaine hydrochloride : 10 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Lidocaine hydrochloride : 2 mg/ml Insulin : 1 UI/ml		619
		Lidocaine hydrochloride : 2 mg/ml Insulin : 1 UI/ml	RL	619
		Lidocaine hydrochloride : 2 mg/ml Insulin : 1 UI/ml		619
		Lidocaine hydrochloride : 8 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Lidocaine hydrochloride : 8 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Lidocaine hydrochloride : 20 mg/ml Ketamine hydrochloride : 2.5 mg/ml		4350
		Lidocaine hydrochloride : 20 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Lidocaine hydrochloride : 10 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Lidocaine hydrochloride : 10 mg/ml Levofloxacine : 5 mg/ml		1072
		Lidocaine hydrochloride : 10 mg/ml Linezolid : 2 mg/ml	∅	1925
		Lidocaine hydrochloride : 10 mg/ml Meropenem : 50 mg/ml		4319
		Lidocaine hydrochloride Methohexital sodium		5060
		Lidocaine hydrochloride : 8 mg/ml Metoprolol tartrate : 1 mg/ml	∅	2346
		Lidocaine hydrochloride : 10 mg/ml Micafungin : 1.5 mg/ml		2108
		Lidocaine hydrochloride : 1 mg/ml Morphine sulfate : 1 mg/ml		62
		Lidocaine hydrochloride : 5 & 10 mg/ml Moxalactam : 333 mg/ml	∅	626
		Lidocaine hydrochloride : 1 mg/ml N-acetylcysteine : 200 mg/ml	∅	3766
		Lidocaine hydrochloride : 0,6 mg/ml Nafcillin sodium : 20 mg/ml		278
		Lidocaine hydrochloride : 0,6 mg/ml Nafcillin sodium : 20 mg/ml		278
		Lidocaine hydrochloride : 1 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Lidocaine hydrochloride : 4 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Lidocaine hydrochloride : 4 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490

		Lidocaine hydrochloride Nitroglycerin		5060
		Lidocaine hydrochloride : 4 mg/ml Nitroglycerin : 0.4 mg/ml	◆	1049
		Lidocaine hydrochloride : 4 mg/ml Nitroglycerin : 0.4 mg/ml	▲	1049
		Lidocaine hydrochloride : 10 mg/ml Palonosetron hydrochloride : 50 µg/ml	◆	2279
		Lidocaine hydrochloride Pantoprazole sodium		2090
		Lidocaine hydrochloride : 10 mg/ml Paracetamol : 10 mg/ml		4742
		Lidocaine hydrochloride : 1 mg/ml Pethidine hydrochloride : 10 mg/ml	◆	62
		Lidocaine hydrochloride : 20 mg/ml Phenylephrine hydrochloride : 2.5 mg/ml	∅	1331
		Lidocaine hydrochloride : 2 mg/ml Phenytoin sodium : 1 mg/ml	▲	619
		Lidocaine hydrochloride : 2 mg/ml Phenytoin sodium : 1 mg/ml	◆	619
		Lidocaine hydrochloride : 2 mg/ml Phenytoin sodium : 1 mg/ml	RL	619
		Lidocaine hydrochloride Piperacillin sodium		3590
		Lidocaine hydrochloride : 8 mg/ml Plazomicin sulfate : 24 mg/ml	▲	4145
		Lidocaine hydrochloride : 20 mg/ml Potassium chloride : 40 mEq/l	▲	730
		Lidocaine hydrochloride : 20 mg/ml Potassium chloride : 40 mEq/l	◆	730
		Lidocaine hydrochloride : 20 mg/ml Potassium chloride : 40 mEq/l	RL	730
		Lidocaine hydrochloride : 2 mg/ml Procainamide hydrochloride : 1 mg/ml	RL	619
		Lidocaine hydrochloride : 2 mg/ml Procainamide hydrochloride : 1 mg/ml	◆	619
		Lidocaine hydrochloride : 2 mg/ml Procainamide hydrochloride : 1 mg/ml	▲	619
		Lidocaine hydrochloride : 10 mg/ml Propafenone hydrochloride : 1 mg/ml	◆	925
		Lidocaine hydrochloride : 10 mg/ml Propofol		660
		Lidocaine hydrochloride : 0,25 & 0,5 mg/ml Propofol : 10 mg/ml	∅	3502
		Lidocaine hydrochloride : 20 mg/ml Propofol : 2 mg/ml	∅	319
		Lidocaine hydrochloride : 10 mg/ml Propofol : 10 mg/ml	∅	300
		Lidocaine hydrochloride : 1.8 mg/ml Propofol : 9 mg/ml	∅	794
		Lidocaine hydrochloride : 1.3 mg/ml Propofol : 8.7 mg/ml	∅	794

		Lidocaine hydrochloride : 1 & 8 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		210
		Lidocaine hydrochloride		619
		Lidocaine hydrochloride : 2 mg/ml Propofol : 8 mg/ml		794
		Lidocaine hydrochloride : 1 & 2 mg/ml Propofol : 10 mg/ml		2053
		Lidocaine hydrochloride : 0.23 >> 0.95 mg/ml Propofol : 9.5 mg/ml		794
		Lidocaine hydrochloride : 0,25 & 0,5 mg/ml Propofol : 10 mg/ml		2053
		Lidocaine hydrochloride : 1 & 8 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
		Lidocaine hydrochloride : 1 & 8 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		210
		Lidocaine hydrochloride : 1 & 8 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
		Lidocaine hydrochloride : 8 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Lidocaine hydrochloride : 10 mg/ml Rocuronium bromide : 10 mg/ml		4828
		Lidocaine hydrochloride : 8 mg/ml Streptokinase : 30000 UI/ml		92
		Lidocaine hydrochloride : 8 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Lidocaine hydrochloride : 8 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Lidocaine hydrochloride : 4 mg/ml Theophylline : 4 mg/ml		317
		Lidocaine hydrochloride : 20 mg/ml Thiopental sodium : 25 mg/ml		319
		Lidocaine hydrochloride Tigecycline		3332
		Lidocaine hydrochloride : 1 & 20 mg/ml Tirofiban : 50 µg/ml		1420
		Lidocaine hydrochloride : 1 & 20 mg/ml Tirofiban : 50 µg/ml		1420
		Lidocaine hydrochloride Tirofiban		1512
		Lidocaine hydrochloride : 4 mg/ml Vasopressin : 2 & 4 UI/ml		1801
		Lidocaine hydrochloride : 2 mg/ml Verapamil hydrochloride : 0,08 mg/ml		706
		Lidocaine hydrochloride : 2 mg/ml Warfarin sodium : 2 mg/ml		315

método de inyección

Bibliografía

	Tipo	Publicación
59	periódico	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	periódico	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
92	periódico	Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 606-608.
187	periódico	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
198	periódico	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
210	periódico	Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807.
214	periódico	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
240	periódico	Lam XM, Ward CA, de C du M?e CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
242	periódico	Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M. Stability of amiodarone hydrochloride in admixtures with other injectable drugs. Am J Hosp Pharm 1986 ; 43: 917-921.
278	periódico	Hagan RL, Carr-Lopez S, Strickland JS. Stability of nafcillin sodium in the presence of lidocaine hydrochloride. Am J Health-Syst Pharm 1995 ; 52: 521-523.
279	periódico	Bailey LC, Cappel KM, Orosz ST. Stability of ceftriaxone sodium in injectable solutions stored frozen in syringes. Am J Hosp Pharm 1994 ; 51: 2159-2161.
288	periódico	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
299	periódico	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.

300	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
315	periódico	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317	periódico	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
319	periódico	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
386	periódico	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
397	periódico	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
398	periódico	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
403	periódico	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.
499	periódico	Rockwell K, Burch K. Intramuscular antibiotic preparation and administration using a 1% lidocaine diluent: policies for the pediatric patient. Hosp Pharm 1991 ; 26: 634-635.
524	periódico	Farquhar Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 1911.
612	periódico	Frable RA, Klink PR, Engel GL, Mundell EE. Stability of cefamandole nafate injection with parenteral solutions and additives. Am J Hosp Pharm 1982 ; 39: 622-627.
619	periódico	Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. Am J Hosp Pharm 1982 ; 39: 1013-1015.
626	periódico	Bornstein M, Lo AY, Thomas PN, Wilham WL. Moxalactam disodium compatibility with intramuscular and intravenous diluents. Am J Hosp Pharm 1982 ; 39: 1495-1498.
660	periódico	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
705	periódico	Lee YC, Malick W, Amann AH, Baaske DM, Shah JJ, Wagenknecht DM, Carter JE. Bretylium tosylate admixture compatibility. II : Dopamine, lidocaine, procainamide, and nitroglycerin. Am J Hosp Pharm 1981 ; 38: 183-187.
706	periódico	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.

730	periódico	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
738	periódico	Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584.
794	periódico	Lilley EMM, Isert PR, Carasso ML, Kennedy RA. The effect of the addition of lignocaine on propofol emulsion stability. Anaesthesia 1996 ; 51: 815-818.
921	periódico	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
925	periódico	Dupuis LL, Trope A, Giesbrecht E, Wong B. Compatibility and stability of propafenone hydrochloride with five critical-care medications. Can J Hosp Pharm 1998 ; 51: 55-57.
1036	periódico	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	periódico	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1049	periódico	Klamerus KJ, Ueda CT, Newton DW. Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm 1984 ; 41: 303-305.
1058	periódico	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1072	periódico	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1126	periódico	Lackner TE, Baldus D, Butler CD, Amyx C, Kessler G. Lidocaine stability in cardioplegic solution stored in glass bottles and polyvinyl chloride bags. Am J Hosp Pharm 1983 ; 40: 97-101.
1193	periódico	Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. Am J Hosp Pharm 1983 ; 40: 1010-1012.
1201	periódico	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1202	periódico	Smith FM, Nuessle NO. Stability of lidocaine hydrochloride in 5% dextrose injection in plastic bags. Am J Hosp Pharm 1981 ; 38: 1745-1747.
1232	periódico	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1315	periódico	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1331	periódico	Das Gupta V, Steward KR. Chemical stabilities of lignocaine hydrochloride and phenylephrine hydrochloride in aqueous solution. J Clin Hosp Pharm 1986 ; 11 : 449-452.

1338	periódico	Baptista RJ, Dumas GJ, Bistrian BR, Condella F, Blackburn GL. Compatibility of total nutrient admixtures and secondary cardiovascular medications. Am J Hosp Pharm 1985 ; 42: 777-778.
1420	periódico	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1490	periódico	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1512	Laboratorio	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1625	periódico	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	periódico	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	periódico	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1715	periódico	Storms ML, Stewart JT, Warren FW. Stability of lidocaine hydrochloride injection at ambient temperature and 4°C in polypropylene syringes. Int J Pharm Compound 2002 ; 6: 388-390.
1721	periódico	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1801	periódico	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	periódico	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	periódico	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	periódico	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1963	periódico	Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am J Health-Syst Pharm 2004 ; 61: 2415-2418.
2053	periódico	Masaki Y, Tanaka M, Nishikawa T. Physicochemical compatibility of propofol-lidocaine mixture. Anesth Analg 2003 ; 97: 1646-1651.
2090	periódico	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	periódico	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.

2269	periódico	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2271	Laboratorio	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
2279	periódico	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2346	periódico	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
2878	periódico	Pascuet E, Donnelly RF, Garceau D, Vaillancourt R. Buffered Lidocaine Hydrochloride Solution With and Without Epinephrine: Stability in Polypropylene Syringes. Can J Hosp Pharm 2009 ; 62, 5: 375-380.
3012	periódico	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3184	Laboratorio	Hyaluronidase (Hyalase®) - Summary of Product characteristics.
3249	periódico	Singhania D, Dedhiya P, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3263	periódico	Donnelly R.F. Stability of buffered lidocaine in glass vials. Can J Hosp Pharm 2011 ; 64, 4: 289-290.
3332	Laboratorio	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3408	periódico	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3420	periódico	El Kateb N, Chaussard M, Bellenger P, Petit A, Faure P. Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology J Oncol Pharm Practice 2014 ; 21, 3: 178-187.
3502	Laboratorio	Propofol (Diprivan®) - Summary of Products Characteristics Astra Zeneca 2012
3546	Laboratorio	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3548	Laboratorio	Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3590	Laboratorio	Piperacilline - Résumé des caractéristiques du produit Dakota Pharm 2011
3687	Laboratorio	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3766	periódico	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3824	periódico	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98

3827	póster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	póster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	póster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	Laboratorio	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3934	Laboratorio	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3964	periódico	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	periódico	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	periódico	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	periódico	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4350	periódico	Beiler B, Barraud D, Vigneron J, Demor? B. Physicochemical stability of an admixture of lidocaine and ketamine in polypropylene syringe used in opioid-free anaesthesia. EJHP 2019 ;0:1-5
4433	periódico	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4457	periódico	Houlihan, S, Decarie, D, Benes, C, Cleve, R, Vidler M, Magee L.A, Ensom M.H.H, vonDadelszen P. Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes. J Obstet Gynaecol Can 2016 ;38,10:936e944.
4528	periódico	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	periódico	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratorio	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4742	periódico	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

4801	periódico	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4828	periódico	Weeks A.L, Sotos J, Woolsey B, Johnston W.M, Cornelius B.W. The Physical Compatibility of Glycopyrrolate and Rocuronium. Anesth Prog 2023 ;70(2):53-57.
4966	Laboratorio	CEFAZOLINE PANPHARMA 1 g, poudre pour solution injectable/pour perfusion - Résumé des caractéristiques du produit. PANPHARMA 2023
4974	Laboratorio	CLOXACILLINE PANPHARMA 1 g, poudre pour solution injectable (I.V.) - Résumé des caractéristiques du produit. PANPHARMA 2021
4981	Laboratorio	KETESSE 50 mg/2 ml, solution injectable/pour perfusion - Résumé des caractéristiques du produit. MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. 2024
5060	Laboratorio	Lidocaine Hydrochloride Injection B.P. 1.0% w/v - Summary of Product Characteristics Updated 09-Nov-2023 ADVANZ Pharma 2023
5090	Laboratorio	TILDIEM 25 mg, poudre et solution pour préparation injectable I.V. - Résumé des caractéristiques du produit. Sanofi 2024

Stabilis

Lidocaine hydrochloride



La estabilidad de las preparaciones farmacéuticas

		5 g ® = Cooper	Emulsan® 14,6 g goma guar 0,4 g	20°C		180			4344
		5 g ® = Cooper	Emulsan® 14,6 g goma guar 0,4 g	40°C		180			4344

Estabilidad en mezcla

		4°C		Epinephrine hydrochloride : Frasco para medicamentos inyectables ® = ? (Nephron) 2,25% 5 Tetracain hydrochloride : Frasco para medicamentos inyectables ® = ? (Winthrop Laboratories) 2% 12,5	182	2437
	Intrasite® 86,45 g	4°C		Oxycodone hydrochloride : Polvo 1,05 g	365	2865
?	Propilenglicol >> Lipoderm® >> 100 g	25°C		Amitriptyline hydrochloride : Polvo ® = ? 2 g Gabapentine : Polvo ® = ? 6 g Ketoprofene : Polvo ® = ? 10 g	14	3971
?	Propilenglicol >> Lipobase® >> 100 g	25°C		Ketoprofene : Polvo ® = ? 10 g Gabapentine : Polvo ® = ? 6 g Amitriptyline hydrochloride : Polvo ® = ? 2 g	28	3971

Bibliografía

	Tipo	Publicación
2437	periódico	Larson TA, Uden DL, Schilling CG. Stability of epinephrine hydrochloride in an extemporaneously compounded topical anesthetic solution of lidocaine, racepinephrine, and tetracaine Am J Health-Syst Pharm 1996 ; 53: 659-662.
2865	periódico	Gebauer MG, McClure AF, Vlahakis TL. Stability indicating HPLC method for the estimation of oxycodone and lidocaine in rectal gel Int J Pharm 2001 ; 223: 49-54.
3971	periódico	Gorman G, Sokom S, Coward L, Arnold J J. Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs. Int J Pharm Compound 2017 ; 21, 2 : 164-170.
4344	periódico	Yay? HS, Faucheron A, Dupont L, El Kouari F, Fekkar A, Bellanger A, Tilleul P. Management of diabetic foot ulcers: a 25% lidocaine topical cream formulation design, physicochemical and microbiological assessments. EJHP 2018

Stabilis

Lidocaine hydrochloride



La estabilidad de las preparaciones farmacéuticas

10 mg Lidocaine oral topical solution USP 2%®		difenhidramina 3,12 mg hidróxido de aluminio 50 mg El hidróxido de magnesio 50 mg Simethicone 5 mg	21°C		21			3978
20 mg Lidocaine oral topical solution USP 2%®		difenhidramina 2,5 mg hidróxido de aluminio 40 mg El hidróxido de magnesio 40 mg Simethicone 4 mg	21°C		21			3978

Bibliografía

	Tipo	Publicación
3978	periódico	Kirk L.M, Brown S.D, Luu Y, Ogle A, Huffman J, O. Lewis P.O. Beyond-use dating of lidocaine alone and in two “magic mouthwash” preparations. Am J Health-Syst Pharm 2017 ; 74,9: 202-210

Diccionario

	Anestésico local		Inyectables
	Nombre comercial		Estabilidad en solucion
	Envase		Molécula
	Concentración		Temperatura
	Conservación		Duración de la estabilidad
	biosimilar		datos contradictorios
	Bibliografía		Vidrio
	Cloruro de sodio 0,9%	?	No precisada
	Día		A cubierto de la luz
	Luz		Glucosa 5%
RL	Ringer lactato	PVC	Cloruro de polivinilo
	jeringa polipropileno	∅	Ninguno
	Estabilidad en mezcla		Solvente
	Molécula		Hora
PP	Polipropileno		Agua para preparación inyectable
?	No precisado		Agua + bacteriostático
	Compatibilidades		Compatible
	Incompatibilidad no especificada		Incompatible
	Precipitación inmediata		Precipitación después de 2 horas.
	Turbidez inmediata	NaH CO3	NaHCO3
	Nutrición parenteral (con lípidos)		específico disolvente
	Inestabilidad química		Precipitación después de 8 horas.
	Precipitación después de 4 horas.		Inestabilidad de la emulsión después de 6 horas.
	Inestabilidad inmediata de la emulsión		Inestabilidad de la emulsión después de 4 horas.
	método de inyección		Intravenoso
	Perfusión intravenosa		Perfusión continua
	Intramuscular		Subcutánea
	Bibliografía		Preparaciones tópicas
	La estabilidad de las preparaciones farmacéuticas		Origine
	Excipiente		Tubo de aluminio para formulaciones tópicas

	Polvo
	Enjuagues bucales
	Diccionario

	Jeringa
	Producto comercial de drogas